ADM03820 / Resilience - LARVOL DELTA

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Ology Bioservices | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Ology Bioservices | Trial completion date: Mar 2023 ➔ Nov 2023 | Trial primary completion date: Mar 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19 (clinicaltrials.gov) - P2/3 | N=0 | Withdrawn | Sponsor: Ology Bioservices | N=4450 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 (clinicaltrials.gov) - P1 | N=50 | Active, not recruiting | Sponsor: Ology Bioservices | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19 (clinicaltrials.gov) - P2/3 | N=4450 | Not yet recruiting | Sponsor: Ology Bioservices | Trial completion date: Aug 2023 ➔ Apr 2024 | Initiation date: Apr 2022 ➔ Jan 2023 | Trial primary completion date: Apr 2023 ➔ Jan 2024

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19 (clinicaltrials.gov) - P2/3 | N=4450 | Not yet recruiting | Sponsor: Ology Bioservices | Initiation date: Dec 2021 ➔ Apr 2022

Trial initiation date • Infectious Disease • Novel Coronavirus Disease

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques. (PubMed, Med (N Y)) - "The Fc-region of two neutralizing mAbs (COV2-2130 and COV2-2381) targeting non-overlapping epitopes on the receptor-binding domain of SARS-CoV-2 spike protein was engineered to extend their persistence in humans and reduce interactions with Fc gamma receptors. These results support clinical development of ADM03820 for COVID-19 prevention. This research was supported by a contract from the JPEO-CBRND (W911QY-20-9-003), 20-05, the Joint Sciences and Technology Office and the Joint Program Executive Office (MCDC-16-01-002 JSTO, JPEO), DARPA grant (HR0011-18-2-0001), NIH grant (R01 AI157155), and the 2019 Future Insight Prize from Merck KGaA."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19 (clinicaltrials.gov) - P2/3; N=4450; Not yet recruiting; Sponsor: Ology Bioservices

Clinical • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Ology Bioservices; Trial completion date: Sep 2021 ➔ Mar 2023; Trial primary completion date: Sep 2021 ➔ Mar 2023

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies (Businesswire) - "Ology Bioservices Inc....announced today that it has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies. This trial is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies. The study will randomize a total of 40 healthy subjects between the ages of 18-55 to receive either an intramuscular injection or intravenous infusion of either ADM03820 or placebo at two clinical sites."

Trial status • Infectious Disease • Novel Coronavirus Disease

This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19 (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Ology Bioservices; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19 (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Ology Bioservices

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease